Prediction of anti-tumour effect of thermochemotherapy with in vitro thermochemosensitivity testing for non-small cell lung cancer
/in International Publications, NSCLC /von 2007-05-01 / Int J Hyperthermia 2007 May;23(3):267-75On verification of hyperthermia treatment planning for cervical carcinoma patients
/in Cervical Cancer, International Publications /von 2007-05-01 / Int J Hyperthermia 2007 May;23(3):303-14TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer
/in International Publications, Prostate Cancer /von 2007-05-01 / Cancer Immunol. Immunother. 2007 Nov;56(11):1785-93[Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy]
/in International Publications, Prostate Cancer /von 2007-05-01 / Zhonghua Nan Ke Xue 2007 May;13(5):453-6AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients
/in Hepatocellular Carcinoma, International Publications /von 2007-05-01 / J. Immunother. 2007 May-Jun;30(4):425-37Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer
/in International Publications, Ovarian Cancer /von 2007-05-01 / Lancet Oncol. 2007 May;8(5):451-4Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression
/in Hypernephroma, International Publications /von 2007-04-20 / Clin. Immunol. 2007 Jun;123(3):298-310Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes
/in International Publications, Malignant Melanoma /von 2007-04-20 / J Transl Med 2007 Apr;5:19DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors
/in Dendritic Cells, Hypernephroma, International Publications /von 2007-04-19 / Cancer Immunol. Immunother. 2007 Nov;56(11):1817-29
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de